Cargando…

Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation

The proteasome inhibitor bortezomib is the most successfully applied chemotherapeutic drug for treating multiple myeloma. However, its clinical efficacy reduced due to resistance development. The underlying molecular mechanisms of bortezomib resistance are poorly understood. In this study, by combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Hongyi, Gu, Yuanliang, Wang, Wenjuan, Wang, Xuyao, Ye, Xiaojuan, Xin, Chao, Lu, Mengjiao, Reddy, B. Ashok, Shu, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972929/ https://www.ncbi.nlm.nih.gov/pubmed/31964975 http://dx.doi.org/10.1038/s41598-020-57698-0

Ejemplares similares

SUMOylation of Dorsal attenuates Toll/NF-κB signaling
por: Hegde, Sushmitha, et al.
Publicado: (2022)

Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation
por: Yang, Qi, et al.
Publicado: (2021)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

NF-κB Repression by PIAS3 Mediated RelA SUMOylation
por: Liu, Yuangang, et al.
Publicado: (2012)

Sumoylation of HDAC2 promotes NF-κB-dependent gene expression
por: Wagner, Tobias, et al.
Publicado: (2015)

SENP1 and SENP2 regulate SUMOylation of amyloid precursor protein
por: Maruyama, Takuma, et al.
Publicado: (2018)

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
por: Markovina, Stephanie, et al.
Publicado: (2010)

The NF-κB Activating Pathways in Multiple Myeloma
por: Roy, Payel, et al.
Publicado: (2018)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells
por: Jia, Li, et al.
Publicado: (2012)

SENP1 and SENP2 affect spatial and temporal control of sumoylation in mitosis
por: Cubeñas-Potts, Caelin, et al.
Publicado: (2013)

Curcumin Enhances Cytotoxic Effects of Bortezomib in Human Multiple Myeloma H929 Cells: Potential Roles of NF-κB/JNK
por: Bai, Qing-Xian, et al.
Publicado: (2012)

HSV-1 ICP27 represses NF-κB activity by regulating Daxx sumoylation
por: Kim, Ji Ae, et al.
Publicado: (2017)

Ginkgolic acid promotes inflammation and macrophage apoptosis via SUMOylation and NF-κB pathways in sepsis
por: Liu, Xinyong, et al.
Publicado: (2023)

Chemoresistance in H-Ferritin Silenced Cells: The Role of NF-κB
por: Aversa, Ilenia, et al.
Publicado: (2018)

SENP7 knockdown inhibited pyroptosis and NF-κB/NLRP3 inflammasome pathway activation in Raw 264.7 cells
por: Li, Xun, et al.
Publicado: (2020)

SENP2 exerts an anti-tumor effect on chronic lymphocytic leukemia cells through the inhibition of the Notch and NF-κB signaling pathways
por: Chen, Xiu-Li, et al.
Publicado: (2018)

Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity
por: Hamdoun, Sami, et al.
Publicado: (2017)

SARS-CoV-2 Nsp5 Activates NF-κB Pathway by Upregulating SUMOylation of MAVS
por: Li, Weiling, et al.
Publicado: (2021)

The SUMOylation of TAB2 mediated by TRIM60 inhibits MAPK/NF-κB activation and the innate immune response
por: Gu, Zhiwen, et al.
Publicado: (2020)

Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2019)

Author Correction: Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2021)

NF-κB and Disease
por: Poma, Paola
Publicado: (2020)

Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma
por: Peng, Huiming, et al.
Publicado: (2011)

NF-κB and the Immunoglobulin κ Gene Enhancer
por: Sen, Ranjan
Publicado: (2004)

Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model
por: Siveen, Kodappully Sivaraman, et al.
Publicado: (2013)

SENP1 participates in the dynamic regulation of Elk-1 SUMOylation
por: Witty, James, et al.
Publicado: (2010)

NF-κB Members Left Home: NF-κB-Independent Roles in Cancer
por: Colomer, Carlota, et al.
Publicado: (2017)

Reversible regulation of ORC2 SUMOylation by PIAS4 and SENP2
por: Wang, Ronghua, et al.
Publicado: (2017)

Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway
por: Roy, P, et al.
Publicado: (2017)

The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF-κB Signaling through miRNA-Induced Silencing of NF-κB–Inducing Kinase
por: Jang, Hanbit, et al.
Publicado: (2020)

Analysis of variation in NF-κB genes and expression levels of NF-κB-regulated molecules
por: Liu-Mares, Wen, et al.
Publicado: (2007)

NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
por: Jayawant, Eleanor, et al.
Publicado: (2023)

PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma
por: Deng, Yi, et al.
Publicado: (2023)

Regulation of Serotonin 1A Receptor SUMOylation by SENP2 and PIASxα
por: Gupta, Sugandha, et al.
Publicado: (2021)

Keeping NF-κB in check
por: Williams, Ruth
Publicado: (2006)

At the crossroads of SUMO and NF-κB
por: Kracklauer, Martin P, et al.
Publicado: (2003)

Slow but steady for NF-κB
por: Leslie, Mitch
Publicado: (2012)

NF-κB in premature aging
por: Osorio, Fernando G., et al.
Publicado: (2012)

Hypoxia Induced NF-κB
por: D’Ignazio, Laura, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0s4edsk58v4b2uvlk5t1pgs0db